Alteplase is a thrombolytic agent that is manufactured by recombinant DNA technology. It is FDA approved for use in acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and occluded catheters. Off-label indications include catheter-directed thrombolysis in the treatment of peripheral arterial occlusive disease and deep vein thrombosis. This activity outlines the indications, contraindications, activity, adverse events, and toxicity of alteplase in the clinical setting as relates to the essential points necessary for members of an interprofessional team managing the care of patients in need of thrombolytic therapy.

**Objectives:**
- Identify the mechanism of action and proper administration of alteplase.
- Summarize the approved indications for alteplase.
- Explain the adverse event profile and potential for toxicity with alteplase.
- Review the importance of coordinating and collaborating among various disciplines in an interprofessional healthcare team to coordinate care and management to enhance outcomes for patients receiving thrombolytic therapy with alteplase.